Completed PHASE2 INTERVENTIONAL 2-arm NCT00124683

Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

Optimizing Treatment for Schizophrenic Smokers

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Schizophrenia Tobacco Use Cessation Tobacco Use Disorder

Interventions Bupropion nicotine transdermal patch

Updated 5 times since 2017 Last updated: Jan 11, 2017 Started: Sep 30, 2001 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Schizophrenia and Tobacco Use Cessation and is currently completed. National Institute on Drug Abuse (NIDA) leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)

Data source: National Institute on Drug Abuse (NIDA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.